about
Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivoPrion disease: experimental models and reality.Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice.Neurological update: gliomas and other primary brain tumours in adults.Evidence of amyloid-β cerebral amyloid angiopathy transmission through neurosurgery.Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and IDH-mutation status prediction: a preliminary study.Inhibition of GPR158 by microRNA-449a suppresses neural lineage of glioma stem/progenitor cells and correlates with higher glioma grades.IDH mutant astrocytoma: biomarkers for prognostic stratification and the next frontiersFetal gene therapy for neurodegenerative disease of infantsPrevalence in Britain of abnormal prion protein in human appendices before and after exposure to the cattle BSE epizooticWorld Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion CoefficientInvited Review: The role of prion-like mechanisms in neurodegenerative diseasesAmyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytesPolycomb-mediated repression of EphrinA5 promotes growth and invasion of glioblastomaRedistribution of EZH2 promotes malignant phenotypes by rewiring developmental programmesSpontaneous generation of prions and transmissible PrP amyloid in a humanised transgenic mouse model of A117V GSSNoninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic responseMicroglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment
P50
Q36635583-13100749-5B1C-436A-9321-7DAE73AFDBF0Q37596801-907FFA42-27A4-4879-BFAE-38FB3BCAF452Q46380539-0454EF2D-9296-431B-A5F7-B43C00CD292DQ47989137-1EBEED38-45DA-4D88-A210-9818E214313DQ49949925-1C2FF140-38EE-4203-B84C-05AEA4AF61C8Q52582028-DCE88E37-AC76-40B2-82BD-67E1F043C178Q52714443-BCF24B4D-A1FA-4645-BBA4-23557E2ED13CQ57459506-C331DAA3-9F85-4192-BA1C-776B6FD0AA81Q59356806-F5BBDA14-21A3-4EC9-A204-858296109496Q90785331-7D7A9F15-F3B3-4249-B405-ADD1C12D9338Q92114582-498C64B6-AE57-4845-83E1-6E8280D2F277Q92202874-28DB7363-22DA-4FEC-B9C4-654EE2A70652Q92916846-02D51D9F-25A4-4D6A-A64B-FBF282533F7AQ92979168-6ADA7B29-7CD9-4105-91BB-A1D119574E8AQ93005015-3EAA7A09-BD13-4DA5-9CF6-66D6F8560F3AQ96223792-C2E9B315-56D0-4557-89DE-D6A2EA857F43Q96230581-3986B373-86B2-4DC3-B7CB-75431264C62BQ96612811-65125AEF-5B91-4F86-992E-1E8C8C7501AB
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-9821-0342
@en
name
Sebastian Brandner
@ast
Sebastian Brandner
@en
Sebastian Brandner
@es
Sebastian Brandner
@nl
type
label
Sebastian Brandner
@ast
Sebastian Brandner
@en
Sebastian Brandner
@es
Sebastian Brandner
@nl
prefLabel
Sebastian Brandner
@ast
Sebastian Brandner
@en
Sebastian Brandner
@es
Sebastian Brandner
@nl
P106
P31
P496
0000-0002-9821-0342